Blood cells may hold key to lung cancer therapy response

NCT ID NCT07363811

Recruiting now Knowledge-focused Sponsor: Necmettin Erbakan University Source: ClinicalTrials.gov ↗

First seen Jan 26, 2026 · Last updated May 21, 2026 · Updated 17 times

Summary

This study is looking at whether a type of immune cell called large granular lymphocytes (LGLs) can help predict how well patients with advanced lung cancer respond to the drug nivolumab. Researchers will measure LGL levels in the blood before and during treatment in 50 participants. The goal is to see if these cells can serve as a simple, early marker of treatment success or failure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology
RECRUITING

Konya, Meram, 42090, Turkey (Türkiye)

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER